Company news
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) news
Nautilus Biotechnology, Inc. news releases on 6ix. Latest, Jul 28, 2026: Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Press releases & updates
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
July 28, 2026
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
July 8, 2026
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
April 28, 2026
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
April 8, 2026
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
March 24, 2026
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
March 20, 2026
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
March 17, 2026
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
March 1, 2026
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
February 25, 2026
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
February 23, 2026
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
February 19, 2026
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 5, 2026
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
January 28, 2026
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
January 8, 2026
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
November 3, 2025
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
October 28, 2025
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
October 7, 2025
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
August 27, 2025
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
July 31, 2025
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
July 30, 2025
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
July 15, 2025
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 27, 2025
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
April 29, 2025
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
April 16, 2025
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
February 27, 2025
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
February 18, 2025
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
October 28, 2024
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
September 16, 2024
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
July 29, 2024
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
April 29, 2024
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
April 10, 2024
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 27, 2024
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
October 31, 2023
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
October 30, 2023
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
October 10, 2023
Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
August 1, 2023
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
July 10, 2023
Nautilus Biotechnology Reports First Quarter 2023 Financial Results
May 1, 2023
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
April 17, 2023
Nautilus Biotechnology Announces “First Access Challenge” Winners
March 6, 2023
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results
February 22, 2023
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
January 25, 2023
Nautilus Biotechnology Expands to San Diego
January 25, 2023
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
January 18, 2023
Nautilus Biotechnology Launches “First Access Challenge”
November 15, 2022
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results
October 31, 2022
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
October 4, 2022
Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
August 31, 2022
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results
August 1, 2022
Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development
July 31, 2022